Latest & greatest articles for Depo Provera

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Depo Provera or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Depo Provera and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Depo Provera

1. Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery (PubMed)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery In the US, obesity rates are increasing greatly. The Centers for Disease Control and Prevention estimates that 68.5% of Americans, including 63.9% of adult women older than 20 years, are overweight (body mass index between 25 kg/m2 and 29.9 kg/m2) or obese (body mass index >30 kg/m2). In light of this, it is not surprising that the rates of bariatric surgery have also been increasing. When considering the metabolic

Full Text available with Trip Pro

2016 Open access journal of contraception

2. CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition

CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition (January 2015) - Faculty of Sexual and Reproductive Healthcare CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition (January 2015) CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition (January 2015) Share

2015 Faculty of Sexual & Reproductive Healthcare

3. Relative cost effectiveness of Depo-provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK

Relative cost effectiveness of Depo-provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK Relative cost effectiveness of Depo-provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK Relative cost effectiveness of Depo-provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK Varney S J, Guest J F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) be a variety of long-term contraceptive options available to consumers in order to provide patients with choice. In doing this, the maximum number of women can be protected and, therefore, the greatest savings to the NHS can be gained. Source of funding Supported by Schering Health Care. Bibliographic details Varney S J, Guest J F. Relative cost effectiveness of Depo-provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK. PharmacoEconomics 2004; 22(17): 1141-1151 PubMedID

2004 NHS Economic Evaluation Database.